Gilead: GS-0976 Leads To Reductions In Measures Of Liver Fat, Fibrosis

Gilead Sciences, Inc. (GILD) announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase or ACC, in patients with nonalcoholic steatohepatitis or NASH.

from RTT - Biotech http://ift.tt/2xk4tD0
via IFTTT